Physician profile
Michael J Duerr
NPI 1043228281
$973.27
in general payments reported to CMS, 2019-2025
10 companies · $91.21 in 2025
The $91.21 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $83.55 · 2021: $139 · 2022: $126 · 2023: $55.87 · 2024: $350 · 2025: $91.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $314.69 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $228.70 | 2019-2024 | Precision 1 |
| Biotissue Holdings INC. | $196.46 | 2020-2024 | |
| Coopervision INC. | $88.25 | 2019-2024 | Myday Contact Lens |
| Dompe US, INC. | $32.28 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.38 | 2021 | |
| Eyevance Pharmaceuticals LLC | $24.87 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $20.02 | 2024 | Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $19.66 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $16.96 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.